ImmunoGen surges as ovarian cancer therapy cuts disease progression risk in study

ImmunoGen

05/06/2023 10:44

** Shares of ImmunoGen Inc  IMGN.O  rise 17.4% to $16.8
before the bell
    ** Company's experimental drug to treat a type of ovarian
cancer  met primary and secondary goals in a late-stage study
    ** The drug candidate when compared to chemotherapy showed
35% reduction in the risk of death or length of time the disease
does not get worse during and after the treatment
    ** The drug demonstrated statistically significant
improvement in length of time patients will survive from
diagnosis of the disease to death
    ** Up to Friday's close, stock has more than doubled YTD

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))